El programa SCALE demuestra el descenso en el ndice apnea-hipopnea en casos de sndrome de apnea del sueo por parte de LIRA frente a placebo (12,2 vs
Geneve, Shakira Rodriguez-Gonzalez, Chia Li, Kaitlyn McElhern, Marc L
tirzepatide is a dual agonist (GIP/GLP-1) Peak weight loss : Retatrutide showed 28.7% at 68 weeks (Phase 3 TRIUMPH-4) and 24.2% at 48 weeks (Phase 2) vs tirzepatide 20.9% (Phase 3) Liver fat : Retatrutide's glucagon agonism provides pronounced hepatic fat reduction (up to 82%) Regulatory status : Tirzepatide is FDA-approved
The available human data comes from smaller studies, often unblinded, and primarily from the Khavinson group
Having something interesting to drink makes social situations more comfortable even when not drinking alcohol
Smaller meals give your stomach a chance to make meaningful progress between eating sessions